Sionna Therapeutics (SION) has approved a restructuring plan to focus resources on its SION-451 and SION-2222 dual combination program for cystic fibrosis. The plan includes a significant workforce reduction and the discontinuation of its SION-719 add-on program, which is expected to extend the company's cash runway.
Key Details
- Workforce Reduction: The company is reducing its workforce by approximately 46% and expects to incur about $5.3 million in severance and related benefit costs.
- Restructuring Charges: Total estimated charges are approximately $6.4 million, which also includes $0.7 million in contract close-out costs for the discontinued SION-719 program.
- Strategic Shift: Resources will be reallocated to advance the SION-451 and SION-2222 dual combination program into a Phase 2a trial, expected to begin in Q1 2027. The changes are projected to extend the company's cash runway into the second half of 2029.
- Management Changes: As part of the restructuring, Chief Business Officer Caroline Stark Beer's employment was terminated, effective September 15, 2026. Other executives, including the CFO and CMO, have assumed expanded roles.